Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label single-arm study of EHT102 for DFNB9 nonsyndromic hearing loss
CTR20260787Phase 2Active
- Sponsor
- Euhearing Therapeutics
- Start
- Mar 2026
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of EHT102 in deafness, nonsyndromic deafness, sponsored by Euhearing Therapeutics. Started Mar 2026; status: active.
02
Drugs
EHT102
03
Conditions
deafnessnonsyndromic deafness
Beyond the preview
Go deeper on CTR20260787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260787.